TorreyPines Therapeutics and Eisai extended their collaboration related to discovery of Alzheimer’s targets by a year. The goal of the genetics research is to identify and validate genes associated with the disease.
Under the terms of the agreement and in connection with the extension, TorreyPines will receive an upfront payment and continued research funding. Eisai will continue to have exclusive rights of first negotiation and refusal for gene targets discovered and validated through the research.
The companies have a separate partnership to find compounds to treat Alzheimer’s, which was also recently extended.